Correction: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans(Diabetologia, (2024), 67, (1877-1896), 10.1007/s00125-024-06193-6)

Elise Wreven, María Soledad Ruiz de Adana, Stéphan Hardivillé, Valery Gmyr, Julie Kerr-Conte, Mikael Chetboun, Gianni Pasquetti, Nathalie Delalleau, Julien Thévenet, Anaïs Coddeville, María José Vallejo Herrera, Liad Hinden, Inmaculada Concepción Benavides Espínola, Mireia Gómez Duro, Lourdes Sanchez Salido, Francisca Linares, Francisco Javier Bermúdez-Silva, Joseph Tam, Caroline Bonner, Josephine M. EganGabriel Olveira, Natalia Colomo, François Pattou, Isabel González-Mariscal*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

Acknowledgment of funding for the project PID2021-128926OA-I00 by MICIU/AEI/10.13039/501100011033 and UE was omitted in the Funding section. The original article has been corrected.

Original languageEnglish
JournalDiabetologia
DOIs
StateAccepted/In press - 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

Fingerprint

Dive into the research topics of 'Correction: Pharmaceutical targeting of the cannabinoid type 1 receptor impacts the crosstalk between immune cells and islets to reduce insulitis in humans(Diabetologia, (2024), 67, (1877-1896), 10.1007/s00125-024-06193-6)'. Together they form a unique fingerprint.

Cite this